Birdeye Adds ChatGPT Model to its AI Platform
Local brands and businesses can now automate review and survey responses with AI PALO ALTO,…
Local brands and businesses can now automate review and survey responses with AI PALO ALTO,…
RESEARCH TRIANGLE PARK, N.C.–(BUSINESS WIRE)–IQVIA (NYSE:IQV) has published its 2022 Environmental, Social and Governance (ESG)…
Sophia Antipolis, France – February 23, 2023 – Thales and LuxCarta, a company specialized in…
WOBURN, MA – 23 February 2023 – Mount Graham Regional Medical Center (MGRMC), Arizona, has…
ANAHEIM, CA, Feb. 23, 2023 (GLOBE NEWSWIRE) — via NewMediaWire – BioCorRx Inc. (OTCQB: BICX)…
TEL AVIV, Israel, Feb. 23, 2023 (GLOBE NEWSWIRE) — SciSparc Ltd. (Nasdaq: SPRC) (“Company” or…
~ Data follow the historic approval of the first gene therapy for hemophilia B, which…
WAKEFIELD, MA, Feb. 23, 2023 (GLOBE NEWSWIRE) — via NewMediaWire – Innovation Pharmaceuticals (OTCQB:IPIX) (“the…
Patent covers 6 novel compositions of matter, which PharmAla has been studying in preclinical testing…
Following the IND clearance, the Company is advancing into a Phase 1 clinical study Potentially…
Company Focuses on Development of Neuromuscular Blocking Agents Phase II Randomized Trial for BX1000 Initiated,…
Positive Phase 3 MAESTRO-NASH study results reported in December 2022 position Madrigal for a resmetirom…
Nes-Ziona, Israel, Feb. 23, 2023 (GLOBE NEWSWIRE) — Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”),…
MARTINSRIED, Germany and MUNICH, Germany, Feb. 23, 2023 (GLOBE NEWSWIRE) — Medigene AG (Medigene, FSE:…
WATERTOWN, Mass., Feb. 23, 2023 (GLOBE NEWSWIRE) — Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology…
BURLINGTON, Mass., Feb. 23, 2023 (GLOBE NEWSWIRE) — scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company…
MORRISTOWN, N.J., Feb. 23, 2023 (GLOBE NEWSWIRE) — Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company…
Conference call scheduled for 4:30 p.m. Eastern Time WALTHAM, Mass., Feb. 23, 2023 (GLOBE NEWSWIRE)…
Treatment with NXP800 resulted in substantial tumor growth inhibition in two in vivo xenograft models…
-Initiated and completed enrollment for EMERALD-1 phase 2a trial of MORF-057 in ulcerative colitis; topline…